Publications in collaboration with researchers from University Medical Center Hamburg-Eppendorf (44)


  1. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

    Haematologica, Vol. 108, Núm. 8, pp. 2192-2204

  2. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188

  3. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

    Advances in Therapy, Vol. 40, Núm. 5, pp. 2412-2425

  4. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 5, pp. 385-393

  5. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Blood Advances, Vol. 7, Núm. 14, pp. 3739-3748

  6. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311

  7. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    HemaSphere, Vol. 7, Núm. 9, pp. E942

  8. Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1600-1609

  9. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269